Key Takeaways
- CEO transition underway, no strategy reset flagged: Pascal Villemagne steps down 31 March; insider Dr. Stephan Fritschi takes over 1 April. The French GMP audit was completed successfully in January, and the second French manufacturing line is now operational.
- Commercial mix drove the quarter, but the model is lumpy: Commercial revenue ran well above the usual 50% share, lifting reported margins, yet commercial volumes do not grow in lockstep with end-market demand because customers split supply chains.
- France is the swing asset for FY26: The site is expected to break even next year, GMP certification is imminent, and new customer wins underpin confidence; the same site caused a covenant breach last year, so delivery is material.
- Balance-sheet repair is now a multi-year commitment: Net leverage target is 1.5x–2.0x within three years, capex stays at $20–25 mn p.a., and interest cost should fall ~INR 10 cr in Q4 as performance improves.
- What to watch next quarter: Whether the French GMP certificate arrives on time, the pace of interest-cost reduction, and any firm bookings from the pickup in development RFQs that management flagged.
CEO Succession & French Milestones
- Orderly handover to an insider: Pascal Villemagne steps down 31 March; Dr. Stephan Fritschi, who describes himself as having come up from bench chemist through the organisation, takes over 1 April. No change in strategy was signalled.
- French GMP audit cleared: The audit, postponed from December to January because of flu, was "extremely successful"; official GMP certification is expected by the end of this quarter.
- Second French line live: The second manufacturing line in France was operationalised in January, removing a bottleneck that had weighed on the site's economics.
- French customer build-up: The business booked a number of important new customers and orders in France, giving management high confidence in achieving its forecast and ambitions for next year.
- France breakeven target: The French entity is expected to break even in the next financial year, a milestone that would also ease the tax-rate distortion caused by loss-making subsidiaries.
Pascal Villemagne: "It's a bit of a bittersweet moment that I have to address to you today as you may have read in the recent news, I'm going to step down from my CEO role at Carbogen Amcis by the end of this fiscal year on the 31st of March."
Revenue Mix & the Commercial-Development Dynamic
- Commercial share ran hot in Q3: Roughly 60% of quarterly revenue came from commercial, versus a usual full-year split of roughly 50-50. For the nine months, the commercial portion has been significantly higher.
- COGS benefit, not a permanent shift: The lower cost of goods sold in Q3 was driven by a higher share of development revenue specifically in November and December, not by a structural margin improvement.
- Commercial growth is capped by customer behaviour: Customers split volumes among multiple suppliers to de-risk their supply chain, so Dishman does not see growth in the same ratio as the end-market product growth. A franchise growing from 100 to 300 crore does not translate proportionally for a single supplier.
- Development pipeline stirring: After a difficult mid-2024, the number of requests from the market is picking up, and management expects to book new projects and new customers "sooner rather than later."
- Phase III to commercial is inherently opaque: Management described forecasting which Phase III projects will reach commercialisation as "like reading in a crystal ball," with a maximum 10% conversion rate.
Pascal Villemagne: "If they have a franchise at 100 crore and it goes at 300 crore. Very often, they are not putting all their eggs in the same basket. So, if we start to be sole supplier at the very beginning, when they start to grow, they add over a supplier to secure their supply chain. So, we don't see that growth on our side because they are dividing their volumes with and among other service provider."
Segment-Level Performance
| Segment | Trend | Commentary |
|---|---|---|
| Swiss activities | ▲ Strong | Driven by commercial productions; expected to achieve "a number above digits" by fiscal year-end. |
| French business | ▲ Inflecting | GMP audit passed, second line operational, new customer wins booked; breakeven targeted next year. |
| India business | ▬ Improving | Performed quite well; next year described as "the real year of turnaround" for India facilities. |
| Netherlands (vitamin D / cholesterol) | ▼ Soft, recovering | Difficult start to the year on vitamin D analogues due to aggressive competition; cholesterol orders now moving in the right direction; Q4 expected to be extremely strong on higher calcifediol sales. |
| ADC / bioconjugation | ▬ Development-stage | Only development revenue currently; commercial production expected FY26–27 after customers obtain market authorisations. |
- Vitamin D margin recovery: Margins are expected to increase in Q4 and going forward on the back of renegotiated wood-risk prices.
- ADC strategy: The company is working on bioconjugations beyond ADCs and is building alliances with commercial partners who can bring antibodies, since it does not have antibody capability in-house.
- Peptide/GLP-1 not a priority: A few confidential requests have been received, but entering that space would require significant capex and knowledge not core to the business.
Balance Sheet, Covenants & Capital Allocation
- Covenant breach resolved in practice: The breach of two financial covenants as of 31 March 2024 stemmed from delays at the French entity, where modification and correction expenses had to be expensed through the P&L, causing a ~INR 50 cr loss in Q4 last year. The plant was deemed ready for operation as of November 2023.
- Interest cost already elevated, now set to fall: Finance cost rose 47% because the covenant breach increased borrowing costs under new terms agreed with the banking syndicate. With improved Q2 and Q3 performance, interest cost should reduce substantially from Q4, by about INR 10 cr in the immediate quarter and from the current INR 48–50 cr range to INR 30 cr in a couple of quarters.
- Net debt nudged lower: Net debt decreased by about CHF 0.5 cr compared to 30 September 2024.
- Leverage target set: Management aims to reduce net leverage to less than 2x, somewhere between 1.5x and 2x, over the next three years.
- Capex disciplined: Capital expenditure for the first nine months was USD 20.8 mn, on track with budget; annual capex is expected to stay at $20–25 mn over the next three years with no significant outlays planned.
- Strategic investment choice: The company chose to invest in drug-product capacity in Switzerland rather than spreading INR 100 cr across multiple sites, driven by a desire to follow up on new molecules.
Margins & Tax
- EBITDA margin drivers: The 9-month EBITDA margin stood at 16%, lifted by the high share of commercial revenue. The full-year FY25 target is 17–18%.
- Employee costs up on FX and increments: The increase in employee expenses was largely driven by rupee depreciation against the Swiss franc and the impact of yearly salary increments.
- Other expenses flattered by a base effect: Q3 FY24 had booked a notional forex loss of almost INR 70 cr on US dollar balances at Carbogen Amcis Switzerland, making the YoY comparison favourable.
- Tax rate optically high, not structurally so: The ~80% calculated tax rate reflects losses in subsidiaries that eat into consolidated PBT; it is not the actual tax rate paid. As the French entity moves closer to breakeven and the Netherlands performs better, the tax rate as a percentage of PBT should improve materially next year.
- Margin trajectory laid out: Current year 17–18%, next year 20%, then 22%, then 24–25% by FY28.
Harshil Dalal: "I think it would still be at about 22, and then it will go to say 24, 25."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| French GMP certification | Official certification expected | By end of current quarter (Q4 FY25) |
| France breakeven | French entity to break even | Next financial year (FY26) |
| Interest cost reduction | Reduce by ~INR 10 cr in Q4; from INR 48–50 cr range to INR 30 cr | Q4 FY25; within a couple of quarters |
| FY25 revenue | ~INR 2,700 cr plus | FY25 |
| FY25 EBITDA | In excess of INR 400 cr | FY25 |
| FY26 EBITDA | Exceeding INR 500 cr | FY26 |
| EBITDA margin trajectory | 17–18% (FY25) → 20% (FY26) → 22% → 24–25% | By FY28 |
| Net leverage | Reduce to 1.5x–2.0x | Within 3 years |
| Annual capex | $20–25 mn p.a. | Next 3 years |
| Revenue CAGR | ~10% over a 3–5 year view | 3–5 year horizon |
| ADC commercial production | Commercial revenue to begin after customers obtain market authorisations | FY26–27 |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Revenue | ₹682 cr, up from ₹505 cr in Q3 FY24 for Carbogen Amcis CRAMS segment |
| 9M revenue | ₹1,995 cr, compared to ₹1,961 cr in 9M FY24 |
| EBITDA | ₹140.6 cr, up 230% YoY from ₹42.5 cr in Q3 FY24 |
| Operating margin | 20.6%, compared to 16% for the 9M period |
| Profit before tax | ₹27 cr, down from ₹42 cr in Q2 FY25 due to higher finance costs |
| Finance cost | ₹48.78 cr, up 47% YoY from ₹33 cr in Q3 FY24 |
| COGS as % of revenue | 14%, an outlier quarter; typical consolidated COGS is 17–18% |
| Carbogen Amcis CRAMS segment margin | 23.7%, up from 19.9% in Q3 FY24 |
| Vitamin D analogues and cholesterol segment margin | 14.6%, down from 16.6% in Q3 FY24 |
| India NCE APIs and Intermediates segment margin | ~11% |
| Quats and Generics segment margin | 7.3% |
| Commercial vs development revenue split | 60% commercial, 40% development, versus a typical 50-50 full-year split |
| Net debt | CHF 16.8 cr, down CHF 0.5 cr from September 30, 2024 |
| 9M capital expenditure | $20.8 million |
| France subsidiary revenue | $3 million in the quarter, with a loss of $1.1 million |
| FY25 revenue guidance | ~₹2,700 cr+ for the full year |
| FY25 EBITDA guidance | ₹425–450 cr for the full year |
| Revenue CAGR outlook (3–5 years) | ~10% |